Chroma: Next Generation UK Biotech
This article was originally published in Start Up
Executive Summary
Recent M&A activity may have led to fewer top ranking UK biotech firms, but far from weakening the sector, it's actually providing opportunities for a newer generation of companies. Chroma Therapeutics Ltd. provides a good illustration of how experienced UK management talent is moving to lead younger, often private firms.
You may also be interested in...
HDAC Inhibitor Mysteries Remain As Candidates Advance
With more than a dozen candidates in the clinic and a range of indications expanding outside oncology, the histone deacetylase inhibitor class could be poised to make major inroads. But much remains to be learned about the activity, and companies are scrambling to find biomarkers.
Triggering Transcription: Seemingly Inactive Genes are On, but 'Stuck in Neutral'
Interest in gene regulatory networks is white hot, encompassing topics as wide ranging as reprogramming skin cells to give them characteristics of embryonic stem cells to the successful development of HDAC inhibitors. Now a research team has shown that many important regulatory genes in adult cells aren't switched off, as had been believed. They're primed to make protein, but something is stopping transcription--possibly a set of master signals that could be modulated with small molecules.
Ex-Shire Team Builds New Euro-Specialty Group
Archimedes joins a growing new generation of pan-European specialty pharma, highlighting the need for a single commercial partner across Europe and the increasing alternatives to big and mid-sized pharma.